Linagliptin vs Prusogliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Linagliptin · Tradjenta
Marketed by Boehringer Ingelheim and partners
NCT00602472 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 1,058 participants, and its primary endpoint was met: adjusted HbA1c change was −0.72% with linagliptin versus −0.10% with placebo (p<0.0001). The evidence is considered moderate because HbA1c is a surrogate measure rather than a hard clinical endpoint.
Reported efficacy
The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years (met)
Result source: NCT01243424
Prusogliptin · Shanzeping
Marketed by CSPC Pharmaceutical Group and partners
NCT04161430 · Phase 3 · completed
In this randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial, 766 patients with type 2 diabetes were randomized to DBPR108, sitagliptin, or placebo. DBPR108 reduced HbA1c significantly more than placebo at 24 weeks, with a treatment difference whose confidence interval excluded no effect.
Reported efficacy
Change from baseline in HbA1c (%) compared to placebo comparator at week 24 (Baseline, week 24): HbA1c change from baseline at week 24: -0.63% (DBPR108) vs -0.02% (placebo); treatment difference -0.61 percentage points (95% CI -0.77% to -0.44%). DBPR108 was superior to placebo. (met)
Result source: NCT04161430
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Linagliptin | Prusogliptin |
|---|---|---|
| HbA1c, change | -0.6% vs 0.1%−0.6 vs placeboNCT00954447129 other results
| -0.6% vs -0.0%a−0.6 vs placeboNCT041614301 other result
|
| Body weight, change (kg) | 1.4 vs -0.0+1.5 vs placeboNCT034295434 other results
| —Not posted · NCT04218734 |
| HbA1c below 7% | 26.9% vs 24.5%+2.4 vs placeboNCT034295437 other results
| —Not posted · NCT04218734 |
| Fasting plasma glucose, change | -0.1 vs 0.0−0.2 vs placeboNCT0095444795 other results
| —Not posted · NCT04218734 |
| 3-point MACE (% with event) | 20.7% vs 21.2%vs GlimepirideNCT012434242 other results
| —Not posted · NCT04218734 |
HbA1c, change
- Linagliptin
- -0.6% vs 0.1%−0.6 vs placeboNCT00954447
129 other results
- -0.7% vs -0.1% NCT00602472
- -0.5% vs 0.1% NCT00601250
- -0.6% vs -0.0% NCT01792518
- -0.7% vs -0.2% NCT01214239
- -0.7% vs -0.1% NCT01215097
- -0.8% vs -0.3% NCT00996658
- -0.8% vs -0.3% NCT01194830
- -0.6% vs 0.0% NCT01084005
- -0.5% vs -0.1% NCT01087502
- -1.1% vs -0.6% NCT00641043
- -0.4% vs 0.3% NCT00621140
- -0.9% vs -0.3% NCT02489968
- -0.6% vs 0.1% NCT01734785
- -0.9% vs -0.3% NCT02489968
- -0.7% vs 0.1% NCT01734785
- -0.6% vs -0.2% NCT02897349
- -1.3% vs -1.6% NCT01708902
- -1.3% vs -1.7% NCT01708902
- 0.3% vs -0.2% NCT03429543
- -0.4% vs -0.7% NCT01183013
- -0.8% vs -0.7% NCT01183013
- -1.1% vs -0.7% NCT01183013
- -1.3% vs -0.7% NCT01183013
- -2.1% vs -1.6% NCT01708902
- -2.3% vs -1.6% NCT01708902
- -2.2% vs -1.7% NCT01708902
- -2.4% vs -1.7% NCT01708902
- -0.6% vs 0.0% NCT00954447
- -0.6% vs 0.0% NCT00954447
- -0.6% vs 0.0% NCT00954447
- -0.5% vs 0.1% NCT00954447
- -0.5% vs 0% NCT00954447
- -0.5% vs 0.1% NCT00954447
- -0.8% vs -0.1% NCT00602472
- -0.7% vs -0.2% NCT01214239
- -0.7% vs -0.2% NCT01215097
- -0.7% vs -0.2% NCT01214239
- -0.6% vs -0.1% NCT01215097
- -0.9% vs -0.4% NCT00996658
- -0.8% vs -0.3% NCT01194830
- -0.6% vs 0.0% NCT01084005
- -0.6% vs -0.1% NCT01214239
- -0.7% vs -0.1% NCT01215097
- -0.8% vs -0.3% NCT00996658
- -0.7% vs -0.2% NCT01194830
- -0.6% vs -0.0% NCT01084005
- -0.5% vs -0.1% NCT01214239
- -0.5% vs -0.0% NCT01215097
- -0.6% vs -0.2% NCT00996658
- -0.5% vs 0.1% NCT00601250
- -0.4% vs -0.1% NCT01084005
- -1.1% vs -0.6% NCT00641043
- -0.5% vs 0.2% NCT00621140
- -0.8% vs -0.1% NCT00602472
- -0.5% vs 0.1% NCT00601250
- -0.8% vs -0.3% NCT00641043
- -0.5% vs 0.2% NCT00621140
- -0.7% vs -0.2% NCT00602472
- -0.4% vs 0.1% NCT00601250
- -0.4% vs -0.0% NCT00641043
- -0.4% vs 0.1% NCT00621140
- -0.6% vs -0.2% NCT01194830
- -0.5% vs 0.1% NCT03429543
- 0.1% vs 0.1% NCT01243424
- -0.4% vs -0.7% NCT01183013
- -0.5% vs -0.5% NCT01087502
- -0.5% vs -0.5% NCT01087502
- -0.5% vs -0.5% NCT01087502
- -0.4% vs -0.6% NCT01183013
- -0.4% vs -0.7% NCT01183013
- -0.5% vs -0.3% NCT01087502
- -0.5% vs -0.4% NCT01087502
- -0.4% vs -0.4% NCT01183013
- -0.5% vs -0.1% NCT01087502
- -0.5% vs -0.1% NCT01087502
- -0.4% vs -0.2% NCT01087502
- -0.2% vs -0.2% NCT01183013
- -0.3% vs -0.1% NCT01087502
- -0.4% vs -0.2% NCT01087502
- -0.4% vs -0.3% NCT01087502
- -0.8% vs -0.7% NCT01183013
- -1.1% vs -0.7% NCT01183013
- -1.2% vs -0.7% NCT01183013
- -0.8% vs -0.6% NCT01183013
- -1.1% vs -0.6% NCT01183013
- -1.2% vs -0.6% NCT01183013
- -0.9% vs -0.7% NCT01183013
- -1.1% vs -0.7% NCT01183013
- -1.3% vs -0.7% NCT01183013
- -0.7% vs -0.4% NCT01183013
- -0.9% vs -0.4% NCT01183013
- -1.0% vs -0.4% NCT01183013
- -0.4% vs -0.2% NCT01183013
- -0.5% vs -0.2% NCT01183013
- -0.6% vs -0.2% NCT01183013
- -0.3% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.4% vs -0.1% NCT00915772
- -0.4% vs -0.1% NCT00915772
- -1.3% vs -1.2% NCT00915772
- -1.7% vs -1.2% NCT00915772
- -0.2% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -1.3% vs -1.2% NCT00915772
- -1.6% vs -1.2% NCT00915772
- -0.3% vs -0.1% NCT00915772
- -0.2% vs -0.1% NCT00915772
- -1.4% vs -1.2% NCT00915772
- -1.7% vs -1.2% NCT00915772
- -1.4% vs -1.3% NCT00915772
- -1.6% vs -1.3% NCT00915772
- -1.3% vs -1.3% NCT00915772
- -1.6% vs -1.3% NCT00915772
- -1.0% vs -0.4% NCT02240680
- -0.5% vs 0.3% NCT01012037
- -0.5% vs 0.3% NCT01012037
- -1.0% vs -1.0% NCT01438814
- -0.6% vs 0.3% NCT01012037
- -0.3% vs 0.3% NCT01012037
- -0.5% vs 0.3% NCT01012037
- -0.3% vs 0.3% NCT01012037
- -0.8% vs -0.8% NCT01438814
- -0.3% vs -0.3% NCT01438814
- 7.6% vs 8% NCT02004366
- 6.6% vs 8% NCT02004366
- 7% vs 8% NCT02004366
- 8.6% vs 8% NCT02004366
- Prusogliptin
- -0.6% vs -0.0%a−0.6 vs placeboNCT04161430
1 other result
- -0.7% vs -0.1% NCT04218734
Body weight, change (kg)
- Linagliptin
- 1.4 vs -0.0+1.5 vs placeboNCT03429543
4 other results
- -2.5 vs -0.3 NCT01734785
- -3.1 vs -0.3 NCT01734785
- 2.7 vs -0.0 NCT03429543
- -0.4 vs -1.1 NCT01438814
- Prusogliptin
- —Not posted · NCT04218734
HbA1c below 7%
- Linagliptin
- 26.9% vs 24.5%+2.4 vs placeboNCT03429543
7 other results
- 13.9% vs 8.2% NCT02897349
- 16.7% vs 24.5% NCT03429543
- 43.6% vs 50% NCT01708902
- 72.1% vs 50% NCT01708902
- 77.1% vs 50% NCT01708902
- 33% vs 10% NCT01012037
- 34% vs 10% NCT01012037
- Prusogliptin
- —Not posted · NCT04218734
Fasting plasma glucose, change
- Linagliptin
- -0.1 vs 0.0−0.2 vs placeboNCT00954447
95 other results
- -0.4 vs -0.2 NCT00954447
- -0.3 vs -0.1 NCT00954447
- -0.4 vs 0.3 NCT00954447
- -0.3 vs 0.2 NCT00954447
- -0.3 vs 0.5 NCT00602472
- -0.5 vs 0.1 NCT01214239
- -0.6 vs -0.1 NCT01215097
- -0.4 vs 0 NCT00954447
- -0.2 vs 0.1 NCT00954447
- -0.6 vs 0.0 NCT00996658
- -0.6 vs 0.6 NCT00601250
- -0.3 vs 0.4 NCT00602472
- -0.6 vs 0.6 NCT00601250
- -0.5 vs 0.3 NCT00602472
- -0.7 vs 0.2 NCT00601250
- -0.6 vs 0.3 NCT00602472
- -0.7 vs 0.3 NCT00601250
- -1.3 vs -0.6 NCT01194830
- -0.6 vs 0.6 NCT01084005
- -0.6 vs -0.1 NCT01214239
- -0.7 vs -0.1 NCT01215097
- -0.5 vs -0.1 NCT00996658
- -0.7 vs 0.5 NCT01084005
- -0.6 vs -0.1 NCT01214239
- -0.8 vs -0.3 NCT01215097
- -0.4 vs -0.0 NCT00954447
- -0.4 vs 0.2 NCT00996658
- -0.8 vs 0.4 NCT01084005
- -0.7 vs -0.0 NCT01214239
- -0.9 vs 0.3 NCT01215097
- -0.2 vs 0.7 NCT00996658
- -0.8 vs 0.3 NCT01084005
- -1.8 vs 0.3 NCT01734785
- -1.5 vs 0.3 NCT01734785
- -1.8 vs -1.0 NCT00641043
- -0.5 vs 0.8 NCT00621140
- -1.8 vs -1.1 NCT00641043
- -0.4 vs 0.7 NCT00621140
- -1.9 vs -1.1 NCT00641043
- -0.6 vs 0.6 NCT00621140
- -1.9 vs -0.9 NCT00641043
- -0.6 vs 0.4 NCT00621140
- 0.2 vs -0.2 NCT01087502
- -0.1 vs -0.1 NCT01087502
- -0.1 vs -0.0 NCT01087502
- -0.1 vs -0.6 NCT01087502
- -0.1 vs -1.6 NCT01183013
- 0 vs -1.4 NCT01183013
- -0.5 vs -0.5 NCT01087502
- -0.8 vs -1.7 NCT01708902
- -0.3 vs -1.2 NCT01183013
- -0.7 vs -0.5 NCT01087502
- -0.3 vs -0.5 NCT01087502
- -0.4 vs -1.1 NCT01183013
- -0.4 vs -1.2 NCT01183013
- 0.0 vs 0.5 NCT01087502
- -0.3 vs 0.3 NCT01087502
- -0.6 vs 0.5 NCT01087502
- -0.2 vs -0.9 NCT01183013
- -0.6 vs 0.5 NCT01087502
- -1.1 vs -1.6 NCT01183013
- -1.5 vs -1.6 NCT01183013
- -1.9 vs -1.6 NCT01183013
- -1 vs -1.4 NCT01183013
- -1.5 vs -1.4 NCT01183013
- -1.9 vs -1.4 NCT01183013
- -0.9 vs -1.2 NCT01183013
- -1.8 vs -1.2 NCT01183013
- -1.8 vs -1.2 NCT01183013
- -1.1 vs -1.1 NCT01183013
- -1.7 vs -1.1 NCT01183013
- -1.7 vs -1.1 NCT01183013
- -1 vs -1.2 NCT01183013
- -1.7 vs -1.2 NCT01183013
- -1.6 vs -1.2 NCT01183013
- -1.1 vs -0.9 NCT01183013
- -1.5 vs -0.9 NCT01183013
- -1.6 vs -0.9 NCT01183013
- -0.4 vs -0.3 NCT00915772
- -0.6 vs -0.3 NCT00915772
- -0.5 vs -0.4 NCT00915772
- -0.7 vs -0.4 NCT00915772
- -0.8 vs -0.4 NCT00915772
- -0.8 vs -0.4 NCT00915772
- -2.2 vs -1.7 NCT01708902
- -2.6 vs -1.7 NCT01708902
- -0.7 vs -0.1 NCT00915772
- -0.7 vs -0.1 NCT00915772
- -0.7 vs -0.2 NCT00915772
- -0.8 vs -0.2 NCT00915772
- -0.7 vs -0.2 NCT00915772
- -0.6 vs -0.2 NCT00915772
- -1.2 vs -0.2 NCT01012037
- -0.9 vs -0.2 NCT01012037
- -1.4 vs -1.5 NCT01438814
- Prusogliptin
- —Not posted · NCT04218734
3-point MACE (% with event)
- Linagliptin
- 20.7% vs 21.2%vs GlimepirideNCT01243424
2 other results
- 11.8% vs 12% NCT01243424
- 12.4% vs 12.1% NCT01897532
- Prusogliptin
- —Not posted · NCT04218734
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Linagliptin: 4 of 4 rows · Prusogliptin: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Linagliptin | Prusogliptin |
|---|---|---|
| Dropout rate | 7.3%a NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 57 more results7.5% NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 4.3% NCT01243424 · Phase 3 0% NCT02467478 · Phase 4 · registry result, not featured evidence 15%5 mg per day NCT02372630 · Phase 4 · registry result, not featured evidence 24% NCT01897532 · Phase 4 · registry result, not featured evidence 5.3%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 0%Linagliptin In-hospital NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin on Discharge NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin+50%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination —Linagliptin+80%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination 20% NCT02350478 · Phase 4 · registry result, not featured evidence 0% NCT01969084 · Phase 4 · registry result, not featured evidence 14%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 11.9%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 4.1%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 5.8% NCT02897349 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 3.8%5 mg NCT01792518 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT01708902 · Phase 3 · registry result, not featured evidence 9.9%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 11.6%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD, then 2.5 mg / Metformin after week 12 NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg NCT01708902 · Phase 3 · registry result, not featured evidence · combination 9.7%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 10.9%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 6.8%2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 22.2%5 mg NCT01183013 · Phase 3 · registry result, not featured evidence 28.6%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 33.8%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 27.8%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 6.8%5 mg NCT01087502 · Phase 3 · registry result, not featured evidence 9%5 mg NCT01214239 · Phase 3 · registry result, not featured evidence 6.8%5 mg once daily NCT01215097 · Phase 3 · registry result, not featured evidence 11.3%5 mg tablet NCT00996658 · Phase 3 · registry result, not featured evidence 2.4%A-GI+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 3.7%Bigu+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 12.1%Glin+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 6.8%Glit+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 7.7%SU+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 24.5%5 mg NCT01194830 · Phase 3 · registry result, not featured evidence 13.9%5 mg NCT00954447 · Phase 3 · registry result, not featured evidence 17%linagliptin 2.5 mg bid + metformin 1000 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 20.4%linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 9.9%5 mg NCT01084005 · Phase 3 · registry result, not featured evidence 21.2% NCT00740051 · Phase 3 · registry result, not featured evidence 5.8% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 5.4% NCT00621140 · Phase 3 · registry result, not featured evidence 4.5%5 mg once daily NCT01012037 · Phase 2 · registry result, not featured evidence 7.2%2.5 mg twice daily NCT01012037 · Phase 2 · registry result, not featured evidence | 0%600 mgb NCT01650324 · Phase 1 · registry result, not featured evidence show 3 more results0%300 mg NCT01650324 · Phase 1 · registry result, not featured evidence 0%100 mg NCT01650324 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01650324 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 2.9%a NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 57 more results1.7% NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 — NCT01243424 · Phase 3 — NCT02467478 · Phase 4 · registry result, not featured evidence —5 mg per day NCT02372630 · Phase 4 · registry result, not featured evidence 10.3% NCT01897532 · Phase 4 · registry result, not featured evidence 4%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence —Linagliptin In-hospital NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin on Discharge NCT02004366 · Phase 4 · registry result, not featured evidence —Linagliptin+50%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination —Linagliptin+80%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination — NCT02350478 · Phase 4 · registry result, not featured evidence 0% NCT01969084 · Phase 4 · registry result, not featured evidence 1.3%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 1.3%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 0.9%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT02897349 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 2.2%5 mg NCT01792518 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT01708902 · Phase 3 · registry result, not featured evidence 4.2%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 2%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD, then 2.5 mg / Metformin after week 12 NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg NCT01708902 · Phase 3 · registry result, not featured evidence · combination 6.9%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 4.8%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.4%2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 3.7%5 mg NCT01183013 · Phase 3 · registry result, not featured evidence 7.9%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 7.5%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 4.5%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 3.4%5 mg NCT01087502 · Phase 3 · registry result, not featured evidence 2%5 mg NCT01214239 · Phase 3 · registry result, not featured evidence 1.5%5 mg once daily NCT01215097 · Phase 3 · registry result, not featured evidence 2.7%5 mg tablet NCT00996658 · Phase 3 · registry result, not featured evidence 1.2%A-GI+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 2.4%Bigu+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 9.1%Glin+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 0%Glit+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 4.9%SU+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 1.8%5 mg NCT01194830 · Phase 3 · registry result, not featured evidence 4%5 mg NCT00954447 · Phase 3 · registry result, not featured evidence 6.4%linagliptin 2.5 mg bid + metformin 1000 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 5.8%linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 4.9%5 mg NCT01084005 · Phase 3 · registry result, not featured evidence 2.6% NCT00740051 · Phase 3 · registry result, not featured evidence 1.5% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 1.5% NCT00621140 · Phase 3 · registry result, not featured evidence 1.3%5 mg once daily NCT01012037 · Phase 2 · registry result, not featured evidence 3.6%2.5 mg twice daily NCT01012037 · Phase 2 · registry result, not featured evidence | —600 mgb NCT01650324 · Phase 1 · registry result, not featured evidence show 3 more results—300 mg NCT01650324 · Phase 1 · registry result, not featured evidence —100 mg NCT01650324 · Phase 1 · registry result, not featured evidence —25 mg NCT01650324 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 3.2%a NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 57 more results3.4% NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 10.4%5 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 46.4% NCT01243424 · Phase 3 7.1% NCT02467478 · Phase 4 · registry result, not featured evidence 0%5 mg per day NCT02372630 · Phase 4 · registry result, not featured evidence 37% NCT01897532 · Phase 4 · registry result, not featured evidence —5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 12.6%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 25%5 mg NCT02240680 · Phase 4 · registry result, not featured evidence 0.8%Linagliptin In-hospital NCT02004366 · Phase 4 · registry result, not featured evidence 13%Linagliptin on Discharge NCT02004366 · Phase 4 · registry result, not featured evidence 15.1%Linagliptin+50%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination 23.1%Linagliptin+80%Glargine Dose on d/ NCT02004366 · Phase 4 · registry result, not featured evidence · combination 15% NCT02350478 · Phase 4 · registry result, not featured evidence 5.3% NCT01969084 · Phase 4 · registry result, not featured evidence 1.3%5 mg NCT01512979 · Phase 4 · registry result, not featured evidence 1.9%5 mg + Metformin NCT01512979 · Phase 4 · registry result, not featured evidence · combination 0.6%5 mg once daily + metformin once daily NCT01438814 · Phase 4 · registry result, not featured evidence · combination 9.6% NCT02897349 · Phase 3 · registry result, not featured evidence 5.2%25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 0.9%10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 9.3%5 mg NCT01792518 · Phase 3 · registry result, not featured evidence 3.6%25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 4.5%10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT01708902 · Phase 3 · registry result, not featured evidence —5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 1.4%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 1.4%5 mg QD NCT01708902 · Phase 3 · registry result, not featured evidence 3.2%5 mg QD, then 2.5 mg / Metformin after week 12 NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.5%2.5 mg / 1000 mg NCT01708902 · Phase 3 · registry result, not featured evidence · combination —2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 1.4%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.7%2.5 mg / 1000 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 0.7%2.5 mg / 500 mg BID NCT01708902 · Phase 3 · registry result, not featured evidence · combination 6.7%5 mg NCT01183013 · Phase 3 · registry result, not featured evidence 7.1%5 mg + 15 mg / 5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 11.3%5 mg + 30 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 7.5%5 mg + 45 mg NCT01183013 · Phase 3 · registry result, not featured evidence · combination 24.8%5 mg NCT01087502 · Phase 3 · registry result, not featured evidence 0.5%5 mg NCT01214239 · Phase 3 · registry result, not featured evidence 2%5 mg once daily NCT01215097 · Phase 3 · registry result, not featured evidence 2.2%5 mg tablet NCT00996658 · Phase 3 · registry result, not featured evidence 8.2%A-GI+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 9.8%Bigu+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 7.6%Glin+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 2.7%Glit+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 4.9%SU+Lina NCT01204294 · Phase 3 · registry result, not featured evidence · combination 0.9%5 mg NCT01194830 · Phase 3 · registry result, not featured evidence 13.8%5 mg NCT00954447 · Phase 3 · registry result, not featured evidence 8.2%linagliptin 2.5 mg bid + metformin 1000 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 5.3%linagliptin 2.5 mg bid + metformin 500 mg bid NCT00915772 · Phase 3 · registry result, not featured evidence · combination 8.6%5 mg NCT01084005 · Phase 3 · registry result, not featured evidence 0.7% NCT00740051 · Phase 3 · registry result, not featured evidence 3.1% NCT00641043 · Phase 3 · registry result, not featured evidence · combination 3% NCT00621140 · Phase 3 · registry result, not featured evidence 2.2%5 mg once daily NCT01012037 · Phase 2 · registry result, not featured evidence 4%2.5 mg twice daily NCT01012037 · Phase 2 · registry result, not featured evidence | 0%600 mgb NCT01650324 · Phase 1 · registry result, not featured evidence show 3 more results0%300 mg NCT01650324 · Phase 1 · registry result, not featured evidence 0%100 mg NCT01650324 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01650324 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a hypoglycaemia 22.7% (placebo 14.8%) upper respiratory tract infection 5.8% (placebo 9.1%) hyperglycaemia 5.6% (placebo 8.7%) NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 50 more resultshyperglycaemia 5.2% (placebo 14.7%) nasopharyngitis 5.2% (placebo 5.1%) NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 20.8% (placebo 12.1%) headache 15.6% (placebo 15.5%) blood ketone body increased 10.4% (placebo 3.4%) NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 hypoglycaemia 29.3% (placebo 28.8%) hypertension 6.2% (placebo 6.7%) hyperglycaemia 6% (placebo 6.9%) NCT01897532 · Phase 4 · registry result, not featured evidence 5 mg hypoglycaemia 33.8% (placebo 25.2%) viral upper respiratory tract infection 7.3% (placebo 5.3%) urinary tract infection 6.6% (placebo 6%) NCT02240680 · Phase 4 · registry result, not featured evidence 5 mg hypoglycaemia 38.5% (placebo 25.2%) viral upper respiratory tract infection 21.2% (placebo 5.3%) bronchitis 9.6% (placebo 2.6%) NCT02240680 · Phase 4 · registry result, not featured evidence infections 5.5% renal 4.7% surgical reintervention 4.7% NCT02004366 · Phase 4 · registry result, not featured evidence gastrointestinal 1.1% musculoskeletal 1.1% skin 1.1% NCT02004366 · Phase 4 · registry result, not featured evidence gastrointestinal 1.1% hematologic 0% infections 0% NCT02004366 · Phase 4 · registry result, not featured evidence · combination gastrointestinal 0% hematologic 0% infections 0% NCT02004366 · Phase 4 · registry result, not featured evidence · combination dorsal pain 5% (placebo 0%) nausea 5% (placebo 4.3%) toothache 5% (placebo 0%) NCT02350478 · Phase 4 · registry result, not featured evidence increased creatinine and bun, reduced gfr 5.3% (placebo 13.6%) pneumonia 5.3% (placebo 0%) cramping in the calf muscle during the graded exercise test 0% (placebo 4.5%) NCT01969084 · Phase 4 · registry result, not featured evidence 5 mg dyslipidaemia 14% hyperglycaemia 12.7% urinary tract infection 8.9% NCT01512979 · Phase 4 · registry result, not featured evidence 5 mg + Metformin dyslipidaemia 8.8% headache 6.3% urinary tract infection 6.3% NCT01512979 · Phase 4 · registry result, not featured evidence · combination 5 mg once daily + metformin once daily diarrhoea 18% abdominal pain 6.7% nausea 6.7% NCT01438814 · Phase 4 · registry result, not featured evidence · combination hypoglycaemia 17.3% (placebo 12.7%) upper respiratory tract infection 13.5% (placebo 12.7%) hyperuricaemia 5.8% (placebo 1%) NCT02897349 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg viral upper respiratory tract infection 26.7% (placebo 22.2%) blood ketone body increased 13.8% (placebo 10.2%) back pain 6% (placebo 2.8%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg viral upper respiratory tract infection 15% (placebo 22.2%) back pain 2.8% (placebo 2.8%) contusion 2.8% (placebo 0.9%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 5 mg hypoglycaemia 13.2% (placebo 5.6%) nasopharyngitis 7.1% (placebo 5.6%) upper respiratory tract infection 2.2% (placebo 5.1%) NCT01792518 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg nasopharyngitis 3.6% (placebo 7.3%) lipase increased 2.7% (placebo 5.5%) urinary tract infection 2.7% (placebo 6.4%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg urinary tract infection 7.1% (placebo 6.4%) nasopharyngitis 4.5% (placebo 7.3%) lipase increased 3.6% (placebo 5.5%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 5 mg diarrhoea 3% hyperuricaemia 3% dizziness 0% NCT01708902 · Phase 3 · registry result, not featured evidence 5 mg QD hyperglycaemia 16.9% hyperuricaemia 5.6% nasopharyngitis 5.6% NCT01708902 · Phase 3 · registry result, not featured evidence 5 mg QD hyperuricaemia 7.5% hyperglycaemia 4.8% upper respiratory tract infection 4.1% NCT01708902 · Phase 3 · registry result, not featured evidence 5 mg QD, then 2.5 mg / Metformin after week 12 hyperuricaemia 19.4% dizziness 6.5% hyperglycaemia 6.5% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 1000 mg hyperuricaemia 6.2% hyperglycaemia 3.1% diarrhoea 1.5% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 1000 mg BID diarrhoea 5.6% hyperuricaemia 5.6% upper respiratory tract infection 5.6% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 1000 mg BID diarrhoea 9.5% hyperuricaemia 7.5% upper respiratory tract infection 7.5% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 2.5 mg / 500 mg BID upper respiratory tract infection 8.2% hyperuricaemia 5.4% diarrhoea 4.8% NCT01708902 · Phase 3 · registry result, not featured evidence · combination 5 mg hyperglycaemia 10.4% nasopharyngitis 7.4% hypertension 6.7% NCT01183013 · Phase 3 · registry result, not featured evidence 5 mg + 15 mg / 5 mg + 30 mg diarrhoea 7.9% nasopharyngitis 7.1% back pain 6.3% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg + 30 mg oedema 9% dizziness 6.8% oedema peripheral 6.8% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg + 45 mg oedema peripheral 11.3% back pain 9% urinary tract infection 5.3% NCT01183013 · Phase 3 · registry result, not featured evidence · combination 5 mg hypoglycaemia 59.3% nasopharyngitis 18.6% hyperglycaemia 17.7% NCT01087502 · Phase 3 · registry result, not featured evidence 5 mg hyperlipidaemia 5.5% (placebo 3%) hyperglycaemia 2% (placebo 4%) NCT01214239 · Phase 3 · registry result, not featured evidence 5 mg once daily hyperglycaemia 4.9% (placebo 5%) hyperlipidaemia 4.4% (placebo 4%) diarrhoea 2.4% (placebo 1%) NCT01215097 · Phase 3 · registry result, not featured evidence 5 mg tablet anaemia 7.1% (placebo 6.7%) hyperglycaemia 6% (placebo 7.9%) hypoglycaemia 5.5% (placebo 4.5%) NCT00996658 · Phase 3 · registry result, not featured evidence nasopharyngitis 41.2% back pain 5.9% constipation 5.9% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 36.6% bronchitis 11% arthralgia 6.1% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 45.5% pharyngitis 7.6% constipation 4.5% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 33.8% upper respiratory tract inflammation 8.1% arthralgia 5.4% NCT01204294 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 31.5% hypoglycaemia 14% contusion 7% NCT01204294 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 6.6% (placebo 3.3%) hyperglycaemia 2.8% (placebo 9.2%) NCT01194830 · Phase 3 · registry result, not featured evidence 5 mg hypoglycaemia 30.3% (placebo 31.3%) hyperglycaemia 14.3% (placebo 17.8%) nasopharyngitis 11.3% (placebo 9.8%) NCT00954447 · Phase 3 · registry result, not featured evidence linagliptin 2.5 mg bid + metformin 1000 mg bid diabetes mellitus 9.9% diarrhoea 7% nasopharyngitis 7% NCT00915772 · Phase 3 · registry result, not featured evidence · combination linagliptin 2.5 mg bid + metformin 500 mg bid hyperglycaemia 12.9% diabetes mellitus 8% glomerular filtration rate decreased 6.2% NCT00915772 · Phase 3 · registry result, not featured evidence · combination 5 mg hypoglycaemia 22.8% (placebo 16.5%) nasopharyngitis 10.5% (placebo 8.9%) diarrhoea 5.6% (placebo 2.5%) NCT01084005 · Phase 3 · registry result, not featured evidence hyperglycaemia 14.6% nasopharyngitis 9.9% dizziness 7.3% NCT00740051 · Phase 3 · registry result, not featured evidence nasopharyngitis 9.3% (placebo 8.5%) upper respiratory tract infection 3.5% (placebo 7.7%) NCT00641043 · Phase 3 · registry result, not featured evidence · combination hyperglycaemia 8.6% (placebo 22.8%) NCT00621140 · Phase 3 · registry result, not featured evidence | 600 mgb haematuria 16.7% (placebo 0%) infection 16.7% (placebo 0%) ligament sprain 16.7% (placebo 0%) NCT01650324 · Phase 1 · registry result, not featured evidence show 3 more results300 mg platelet count decreased 16.7% (placebo 0%) haematuria 0% (placebo 0%) infection 0% (placebo 0%) NCT01650324 · Phase 1 · registry result, not featured evidence 100 mg haematuria 0% (placebo 0%) infection 0% (placebo 0%) ligament sprain 0% (placebo 0%) NCT01650324 · Phase 1 · registry result, not featured evidence 25 mg haematuria 0% (placebo 0%) infection 0% (placebo 0%) ligament sprain 0% (placebo 0%) NCT01650324 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 55 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Linagliptin
show 95 more results
show 12 more results
show 9 more results
show 1 more result
show 7 more results
show 4 more results
show 4 more results
show 1 more result
show 1 more result
+ 59 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Linagliptin's landscape · Prusogliptin's landscape